RG1068 (Synthetic Human Secretin)
Sponsors
Repligen Corporation, Indiana University School of Medicine, Massachusetts General Hospital
Conditions
Acute Recurrent PancreatitisAutismChronic PancreatitisIntraductal Papillary Mucinous NeoplasmsObsessive Compulsive Disorder (OCD)Pancreatitis
Phase 1
Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population
TerminatedNCT00621283
Start: 2008-02-29End: 2008-12-31Updated: 2009-01-29
Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas
TerminatedNCT00621556
Start: 2008-02-29End: 2008-12-31Updated: 2009-01-29
Secretin Enhanced Multidetector CT Pancreatography for Evaluation of Known or Suspected Chronic Pancreatitis
TerminatedNCT00620919
Start: 2008-02-29End: 2008-12-31Updated: 2009-01-29
Phase 2
Phase 3
Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
TerminatedNCT00036231
Start: 2002-04-30Updated: 2005-11-21
Synthetic Human Secretin in Children With Autism
CompletedNCT00036244
Start: 2002-04-30End: 2004-01-31Updated: 2005-08-05
Safety and Efficacy of Synthetic Human Secretin-Enhanced MRCP in Subjects With Abnormalities of the Pancreas
CompletedNCT00660335
Start: 2008-03-31End: 2009-10-31Updated: 2009-12-03